<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77291">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01974245</url>
  </required_header>
  <id_info>
    <org_study_id>CNPq473838/2011-7</org_study_id>
    <nct_id>NCT01974245</nct_id>
  </id_info>
  <brief_title>Supplementation With Cholecalciferol in Dialysis Patients</brief_title>
  <official_title>Impact of Treatment With Cholecalciferol on Immunological Markers in Patients With Hypovitaminosis D on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypovitaminosis D is highly prevalent among patients with chronic kidney disease, especially
      in those undergoing dialysis. The loss of protein to the dialysis solution seems to
      contribute significantly to the reduced serum levels of vitamin D in these patients. As a
      result of the disease and the dialysis procedure, there is high prevalence of chronic
      inflammation and high risk of infections. There is evidence in other populations, that
      vitamin D has immunomodulatory effects by stimulating the production of cathelicidin, an
      antimicrobial peptide and suppressing the production of proinflammatory cytokines. Thus,
      this study aims to investigate the effects of cholecalciferol supplementation on
      immunological markers in patients in hemodialysis and peritoneal dialysis with
      hypovitaminosis D . This is a randomized, double-blind, placebo-controlled trial in which
      patients who have vitamin D deficiency [25 (OH) D &lt;20 ng / mL] will be allocated to the
      intervention group (cholecalciferol) or control (placebo). Patients will receive
      supplemented 100,000 IU / week cholecalciferol a period of 12 weeks. Before and after the
      intervention will be determined 25(OH)D, cathelicidin, interleukin-6 (IL-6), tumor necrosis
      factor-α (TNF-α) and C-reactive protein serum. In monocytes, we will evaluate cathelicidin,
      IL-6 and TNF-α, 25(OH)D receptor and α 1-hydroxylase enzyme expression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction of immunological markers with cholecalciferol supplementation at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of normalization of 25(OH)D level after cholecalciferol supplementation at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Expression of 25(OH)D receptor and α 1-hydroxylase enzyme with cholecalciferol supplementation at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>The placebo group did not present effects on immunological markers, 25(OH)D levels and 25(OH)D receptor and 1-alfa hydroxylase enzyme after cholecalciferol supplementation at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 drops/week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Cholecalciferol - 100,000 IU/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>100,000 IU/week for 12 weeks</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <other_name>Vitamina D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25 (OH) &lt; 20 ng/ml

          -  Peritoneal dialysis or hemodialysis &gt; 3 months

        Exclusion Criteria:

          -  Use of vitamin D or its analogues, corticosteroids and immunosuppressive

          -  Peritonitis in the previous month at baseline

          -  Liver, neoplastic, infectious or autoimmune diseases and positive HIV

          -  Hypercalcemia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilian Cuppari, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marion S Meireles, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria A Kamimura, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion S Meireles, Master</last_name>
    <phone>55 11 59048482</phone>
    <email>mariondschneider@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lilian Cuppari, PhD</last_name>
    <phone>55 11 59048480</phone>
    <email>lcuppari@uol.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04039-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion S Meireles, Master</last_name>
      <phone>5511 59048482</phone>
      <email>mariondschneider@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lilian Cuppari, PhD</last_name>
      <phone>5511 59048480</phone>
      <email>lcuppari@uol.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Marion S Meireles, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria A Kamimura, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lilian Cuppari, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Lilian Cuppari, PhD</investigator_full_name>
    <investigator_title>Afilliate Professor</investigator_title>
  </responsible_party>
  <keyword>Cholecalciferol</keyword>
  <keyword>Kidney diseases</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
